Key Takeaways
- Strong quarter, guidance raised: Revenue grew 30% YoY to ₹316 crores, and management now expects to exceed its original FY27 guidance of 15% revenue growth and 20% EBITDA margin.
- Backward integration is the structural moat: Gross margin expanded to 35%, and the company’s control over ibuprofen intermediates provides stability and supply assurance that non-integrated peers lack.
- Ibuprofen is booming but will be capped: The ARV segment grew 47% in H1, but management intends to keep single-product dependency below 35% of total revenue as new molecules scale.
- Peptides are the next growth vector, but early: A new subsidiary, dedicated CEO, and R&D facility are in place, yet pilot samples are not expected until Q4 FY27 and meaningful revenue is 2–3 years away.
- What to watch next quarter: The pace of ibuprofen capacity ramp-up to 9,600 tons, the trajectory of raw material price hikes, and any initial customer engagement on peptides.
Performance & Margin Drivers
- Broad-based volume and price growth: Q2 revenue growth was driven by roughly 10–15% volume growth in kgs alongside price hikes, with raw material price pressure persisting but selling prices also increased.
- H1 profitability leap: H1 FY27 PAT grew 36% YoY to ₹59.8 crores, with EBITDA margin at 21%, aided by operating leverage and a richer mix of high-value APIs.
- High-value API mix shift: High-value APIs climbed to 49% of H1 revenue from 47% in FY26, driven by market share gains in products where economies of scale and backward integration provide structural advantage.
- Working capital cycle structurally improved: Working capital days have moved from an older range of 180–220 days to a current cycle of roughly 120–150 days, with H1 cash flow conversion around 93–95% versus a long-term average closer to 72%.
- Gross margin dipped sequentially but expanded YoY: Gross margin at 35% was slightly below Q1’s 36% but well above the prior year’s 32%, with the YoY expansion attributed to backward integration benefits.
Potluri: "Backward integration gives us a structural cost advantage, not a temporary pricing benefit. And this quarter shows that clearly. It reflects 5 years of investments in backward integration and capacity building."
Ibuprofen: Capacity, Stability & Dependency
- Utilization near full on existing base: Current ibuprofen capacity of roughly 400–500 tons per month is running at 90–95% utilization, with volumes ramping up from day one rather than operating at a fixed full-year base.
- Capacity expansion nearing completion: Remaining capex is expected to finish in the coming quarters, taking total ibuprofen capacity to 9,600 tons per year, with full utilization at 90% occupancy expected within 6 to 8 months of completion.
- Backward integration ensures supply stability: Control over intermediates means the company can deliver ibuprofen despite global price escalations, a structural advantage management argues non-integrated peers lack.
- Cost reduction is an ongoing process: Batch sizes are close to 10 tons and growing, with continuous efforts to reinvent and reduce costs; management describes the manufacturing process as one of the best in the market.
- Dependency deliberately capped: Management will keep ibuprofen below 35% of total revenue to avoid becoming a single-product company, even as the product enjoys strong demand and pricing.
- Derivatives offer higher margins at lower volumes: Multiple ibuprofen salts are already validated with CEPs and DMFs filed; margins on derivatives are much higher than regular ibuprofen, though volumes are much lower.
Potluri: "More important than the margins, the stability on the product... if we were not backward integrated, we would have been caught napping and we wouldn't have -- we wouldn't actually have the product to -- the intermediate to actually manufacture ibuprofen."
Peptides: Early-Stage Build-Out
- Dedicated subsidiary and leadership in place: SMS Peptides Private Limited, a 99.9% owned subsidiary, has been set up with a fully operational R&D facility and a dedicated CEO leading a separate team.
- Timeline is back-end loaded: R&D started only a couple of months ago; no samples have been sent to customers yet, and pilot-level peptide samples are expected only by Q4 FY27.
- First revenue still distant: First CRO revenue from the peptides subsidiary is expected in Q2 FY28, with meaningful revenue anticipated only in the next 2 to 3 years.
- Generic peptides, not a CRO play for now: The initial focus is on in-house generic peptide development rather than a CRO opportunity, with pilot scale targeted for Q4 FY27.
- Margin potential is attractive: Management notes that peptides typically carry margins of 40% plus, and the FY29 patent cliff is identified as a potentially huge opportunity.
- Team building still underway: Recruitment for the peptides R&D team is ongoing, and management acknowledges it may take time to attract top industry names for CRO and CDMO work.
Potluri: "It might take a little while for us to attract the real top names in the industry to come and work on CRO and CDMO with us. But definitely, I think in the next 2 to 3 years, we anticipate a meaningful revenue coming out from the peptides."
Capex, New Molecules & Balance Sheet
- ₹280 crore capex program on track: The program remains on schedule for completion by FY27, adding capacity for existing molecules and 6 to 8 new pipeline molecules, with roughly ₹120 crores still to be deployed.
- New molecule launches in FY28: 6 to 8 new molecules are expected to start commercial production in FY28, covering anti-ulcer, anti-migraine, antidepressant, antifungal and antifibrotic APIs; as they scale over the following six quarters, they are expected to be EBITDA accretive and diversify revenue.
- Peak debt expected around ₹400 crores: Long-term plus short-term debt is anticipated to peak around ₹400 crores by the end of FY27, reflecting the ongoing capex cycle.
- Fixed asset turnover expected to improve: Current fixed asset turnover stands at 1.72x excluding CWIP, with improvement anticipated as new capacities come online and generate revenue.
- Board loan to peptides subsidiary: The board approved a ₹50 crore loan to SMS Peptides Private Limited to support its expansion.
Segment & Partnership Dynamics
| Segment | H1 FY27 Trend | Commentary |
|---|---|---|
| ARVs | ▲ Strong growth | Grew 47% YoY to ₹150 crores on market share gains. |
| Anti-inflammatory | ▲ Solid growth | Grew 25% YoY to ₹110 crores, driven by ibuprofen demand from regulated markets. |
| High-value APIs | ▲ Mix improving | Share climbed to 49% of H1 revenue from 47% in FY26, with structural advantage from scale and backward integration. |
| Chemo partnership | ▬ Steady | Nearly 10-year partnership ongoing; products like sitagliptins and flozins developed under a JV with profit share. |
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY27 revenue and margin | Exceed original guidance of 15% revenue growth and 20% EBITDA margin | FY27 full year |
| Ibuprofen capacity | Reach 9,600 tons per year total capacity | Coming quarters |
| Ibuprofen full utilization | Achieve 90% occupancy of 9,600-ton capacity | 6–8 months after capacity completion |
| Capex program completion | Deploy remaining ~₹120 cr of ₹280 cr program | By end of FY27 |
| New molecule commercial production | 6–8 new molecules begin commercial production | FY28 |
| Peptides pilot scale | Pilot-level peptide samples produced | Q4 FY27 |
| Peptides first CRO revenue | First CRO revenue from peptides subsidiary | Q2 FY28 |
| Peptides meaningful revenue | Meaningful revenue contribution from peptides | Next 2–3 years |
| Ibuprofen dependency cap | Keep ibuprofen below 35% of total revenue | Ongoing |
| Working capital cycle | Maintain 120–150 day cycle | Going forward |
| FY28 EBITDA margin | Achieve 22%–24% EBITDA margin | FY28 |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹316 cr, +30% YoY and +53% QoQ |
| Gross profit | ₹111 cr, +41% YoY |
| Gross margin | 35%, vs 32% in Q2 FY26 and 36% in Q1 FY27 |
| EBITDA | ₹68 cr, +40% YoY |
| EBITDA margin | 21%, expanded 145 bps YoY |
| PAT | ₹39.6 cr, +57% YoY |
| PAT margin | ~13% |
| H1 FY27 revenue | ₹523 cr, +19% YoY |
| H1 FY27 EBITDA margin | 21% |
| H1 FY27 PAT | ₹59.8 cr, +36% YoY; including VKT profit share: ₹60.8 cr, +33% YoY |
| FY27 revenue growth guidance | Exceeding 15%, original guidance was 15% |
| FY27 EBITDA margin guidance | Exceeding 20%, original guidance was 20% |
| FY28 EBITDA margin target | 22% to 24% |
| High-value APIs share of revenue | 49% in H1 FY27, up from 47% in FY26 |
| Ibuprofen capacity utilization | 90% to 95% of existing capacity |
| Ibuprofen monthly production | 450 to 500 tons |
| Ibuprofen total capacity target | 9,600 tons per year, capex to complete in coming quarters |
| Capex deployed | ₹160 cr of ₹280 cr program, on track for completion by FY27 |
| Peak debt expected by end of FY27 | ~₹400 cr, long-term and short-term combined |
| Working capital cycle | 120 to 150 days |
| H1 FY27 cash flow conversion ratio | ~93% to 95% |
| Fixed asset turnover (excl. capital WIP) | 1.72x |
| R&D filings in FY27 | 6 filings so far (4 in H1, 2 in October), FY27 target of 10 |
| New molecules for commercial production in FY28 | 6 to 8 |
| Peptides R&D team | ~30 chemists, mostly PhDs |
| Loan approved for SMS Peptides subsidiary | ₹50 cr |